Mass tort intake runs on a fundamental mismatch. The ad campaign can generate a large volume of inbound leads quickly. The case manager can evaluate a small number of leads carefully. The gap between those two rates is where firms lose money, and it is the gap that a structured qualification system is built to close.
These nine steps describe how to filter a mass tort lead from first contact to a case manager's desk. Each one removes a category of leads that cannot become cases, before staff time is spent on them.
Quick answer: 9 ways to qualify mass tort leads
- Confirm exposure or product use falls within the qualifying window
- Screen for a physician-confirmed diagnosis tied to the specific tort injury
- Check whether the lead has already filed a settlement or bankruptcy trust claim
- Verify the lead has not already signed with another firm
- Ask litigation-specific intake questions that match the MDL's case criteria
- Flag any missing medical records that the claim will require
- Run a short pre-screen call before committing to a full intake
- Route borderline leads to a secondary review step rather than a binary decision
- Tag every disqualified lead with a reason code and send it back to the ad platform
1. Confirming exposure or product use within the qualifying window
Every mass tort has a defined exposure or product-use window. A lead who used the product outside that window cannot become a viable case, and that date must be captured at the first point of contact.
The qualifying window is set by the litigation itself, sometimes by the MDL court's case management orders, sometimes by settlement class definitions, sometimes by statute of limitations analysis tied to when a claimant knew or should have known about their injury. The specific dates vary by tort.
What does not vary is the principle: intake must ask for the date of use, purchase, prescription fill, or device implant at the very first touchpoint, whether that is a landing page form, an instant form on Meta, or the opening of a phone screen. A lead who cannot provide a date within the window is a disqualified lead. Sending that lead to a case manager before that confirmation wastes thirty minutes of capacity that could go to a qualifying claimant.
Practical takeaway: Build the exposure date question into the landing page form or the first thirty seconds of the pre-screen call. Treat a missing or out-of-window date as a hard stop, not a follow-up item.
2. Screening for a documented diagnosis or injury tied to the tort
A physician-confirmed diagnosis tied to the specific tort injury is a hard qualification criterion in most mass tort litigations. Self-reported symptoms alone do not make a claim viable.
The distinction matters at intake because advertising for mass torts reaches a broad audience. Some portion of respondents will have used the product and will have experienced symptoms, but will not have received a formal diagnosis from a licensed provider. Depending on the tort, that absence is a disqualifying gap: no diagnosed injury, no medical records to substantiate the claim, no viable case file.
The intake question is not "have you been hurt?" It is "have you been diagnosed by a doctor with a specific condition, and what is that condition?" The intake screen should capture the diagnosing provider, the approximate date of diagnosis, and whether the claimant has documentation. Those three data points determine whether the lead belongs in the active pipeline or the flagged-records bucket described in step six.
Practical takeaway: Train intake staff or configure intake forms to ask for the diagnosis, the diagnosing provider, and the date. A yes to "I feel like I was harmed" is not a qualifying answer.
3. Checking prior settlement or bankruptcy trust claims already filed
If a lead has already received a settlement or filed a claim through a bankruptcy trust for the same injury and the same product, they are typically barred from additional recovery in that litigation.
Many high-volume mass torts, particularly those involving asbestos, talc, or opioid manufacturers, resolve through structured bankruptcy trusts after the defendant files for Chapter 11. A claimant who has already filed with the trust or received trust compensation for the same injury and product has typically released their claim. Signing that lead and building a case file is work that will not produce a recoverable case.
The intake screen should ask directly: have you previously filed a claim, received a settlement, or signed a release related to this product or injury? The answer does not require legal interpretation at the intake level. A "yes" routes the lead to a secondary review step. A "not sure" also routes to secondary review. A clear "no" passes this checkpoint and moves forward.
Practical takeaway: Make the prior-claim question a required field on the intake form. Route any affirmative or uncertain answer out of the primary pipeline for review before a retainer is generated.
4. Verifying the lead has not already signed with another firm
A lead who is already represented by another attorney cannot be signed by a second firm. Taking on a represented claimant creates an ethical conflict and produces no recoverable case.
This question belongs in the first sixty seconds of any intake interaction. It can appear on the pre-screen form: "Are you currently represented by an attorney for this claim?" A yes ends the intake. A no passes the lead forward.
Some leads are uncertain. They spoke to another firm but did not sign a retainer. They received a mailer but did not respond. Uncertainty here goes to secondary review, not to a case manager doing a full intake.
The operational point for a firm running mass tort marketing is that the ad campaign will reach claimants who have already responded to other firms' ads. In a high-advertising tort, the overlap is not small. A representation-status check at intake is not a formality. It is a meaningful filter.
Practical takeaway: Add a representation-status question to the intake form as a required field. Treat uncertainty as a secondary review trigger, not a pass-through.
5. Asking targeted intake questions specific to the litigation
Each mass tort has case-type-specific facts that determine whether a claimant fits the MDL class or settlement criteria. Generic intake questions miss these facts. A lead who passes the generic screen may still fail the litigation-specific screen.
The specifics vary. A pharmaceutical tort may require a particular NDC drug code, a minimum daily dose, or a minimum duration of use. A medical device tort may require a specific device model or lot number. A consumer product tort may require purchase within a defined retail channel. These are not questions a general intake script covers.
Firms managing multiple mass tort campaigns simultaneously need a separate intake question set for each tort, and those question sets need to be updated when the litigation's case criteria change, which they do, particularly in active MDLs. Feeding an outdated intake script to a lead who may qualify under current criteria means losing a case that was there to be signed.
Practical takeaway: Build a litigation-specific intake question set for each active tort campaign. Review and update it when the MDL issues new case management orders or when the settlement class definition changes.
6. Flagging leads missing medical records needed for case build
Medical records are required to substantiate most mass tort claims. Many claimants do not have them in hand when they call or fill out a form. The intake process should determine, for every lead who passes the earlier screens, whether the required records exist and whether the claimant can obtain them.
Signing a retainer with a claimant who cannot locate or obtain their medical records creates a stalled case file. The records request, the follow-up, the waiting period, and ultimately the possibility that the records cannot be retrieved all happen after signing. If those problems surface before signing, the firm can decide whether to invest in helping the claimant obtain records or whether the lead belongs in a lower-priority status.
The intake screen should ask: do you have your medical records, or do you know the provider who treated you for this condition? A yes to either passes the checkpoint. A no to both creates a flag in the CRM record that signals a records-gap case before any case manager time is invested.
Practical takeaway: Add a medical-records status question to the intake screen. Create a CRM tag or pipeline stage for records-gap leads so they receive a different follow-up sequence than fully qualifying leads.
7. Using a short pre-screen call before full intake to save time
A two-to-three-minute pre-screen call that confirms the top hard disqualifiers protects case manager capacity more than running a full intake on every inbound lead.
The economics of mass tort intake are straightforward. A full intake call runs thirty minutes or more. A case manager can run a limited number of those per day. If a meaningful share of inbound leads are disqualified by the first three or four criteria, running a short pre-screen before the full intake changes the math. The pre-screen confirms exposure date, diagnosis status, representation status, and any single litigation-specific hard criterion. A lead who fails any one of those four does not reach the full intake queue.
The pre-screen can be handled by a trained intake coordinator rather than a case manager. It can also be handled by an automated AI intake system that runs the pre-screen questions before routing, as long as any handoff to a person is prompt for leads who pass. The point is that case manager time is the constrained resource, and the pre-screen step protects it.
Practical takeaway: Build a pre-screen step into the intake workflow that runs the top four hard disqualifiers in under three minutes before any lead enters the full intake queue.
8. Routing borderline leads to a secondary review step
Leads with partial qualifying facts, such as a confirmed diagnosis but an uncertain exposure date, belong in a secondary review step, not a flat disqualification or an automatic retainer.
Binary intake logic, either a case or not a case, mishandles borderline leads in two directions. A lead with a confirmed diagnosis and a plausible exposure date but an uncertain exact date may be a qualifying case once additional facts are gathered. Disqualifying that lead outright loses a case the firm could have signed. Passing it to a case manager without flagging the uncertainty means the case manager works a full intake on something that may still fail.
Secondary review is a named pipeline stage. A dedicated reviewer, often a paralegal or a senior intake coordinator, looks at the specific gap, determines whether it can be resolved, and either upgrades the lead to the full intake queue or disqualifies it with a reason code. This step handles leads that the pre-screen could not cleanly resolve.
For a firm running volume in a mass tort with high inbound lead counts, secondary review is not optional overhead. It is the mechanism that recovers cases the binary system would discard and prevents bad cases from consuming full intake capacity.
Practical takeaway: Create a secondary review pipeline stage in the CRM. Assign ownership to a specific team member and set a maximum review-to-decision time so borderline leads do not age out without a decision.
9. Tagging disqualified leads with a reason code for ad feedback
Recording why a lead was disqualified and sending those reason codes back to the ad platform lets the campaign bid away from the audience segments producing unqualifiable leads.
Most mass tort campaigns generate a disqualification pattern. One audience segment consistently sends leads who used the product outside the qualifying window. Another sends leads who have already filed trust claims. A third sends leads who are unrepresented and have a confirmed diagnosis but cannot locate medical records. Each pattern points to a different problem in the ad targeting or the creative.
Without reason codes, all disqualified leads look the same to the campaign: a form fill that did not become a signed case. With reason codes captured in the CRM and sent back to Meta or Google as offline signals, the platform's algorithm can see which audience attributes correlate with which disqualification types. The campaign then allocates budget away from the segments producing the most unqualifiable leads and toward the segments producing leads that pass the full intake screen.
This is the connection between intake qualification and ad performance. The intake team's disqualification decisions, when they are tagged and fed back through a conversion tracking pipeline, directly improve the cost per qualified lead over time. A campaign that only receives "signed case" as a signal is missing the intermediate data that explains why some leads sign and others do not.
Practical takeaway: Define a standard set of disqualification reason codes in the CRM. Build an automated feed of those codes back to the ad platform as offline conversion events, mapped to the click ID captured at the point of first contact.
How the qualification steps connect to the ad system
The nine steps above are intake protocol. The system that makes them compound is the ad-to-CRM-to-platform feedback loop.
A lead who fills out a Meta ad form carries a click ID. That click ID follows the lead through the CRM record from the moment it is created. When the lead is disqualified at step two because there is no confirmed diagnosis, the reason code and the click ID travel back to Meta as an offline event. Meta's system logs that this particular audience profile, at this placement, with this creative, produced a lead that failed the diagnosis screen. Over time, and at sufficient volume, the algorithm adjusts.
The same logic applies to signed cases. When a lead passes all nine screens and signs a retainer, the signed-case event goes back to the platform. The campaign learns what a qualifying mass tort case looks like, not what a form fill looks like.
CRM automation and AI-powered lead response are what make this feedback loop run without manual exports. The CRM records the reason code. The automation fires the offline event. The platform receives the signal. Case managers never touch that process.
For firms running mass tort campaigns where the cost per acquired lead is high and the cost per signed case is higher, the qualification system is not a separate function from the marketing system. It is the part of the marketing system that determines whether the ad spend produces ROI.
If you want to see how the intake qualification steps map to your current campaign structure, a Case Acquisition Review covers the full pipeline in 30 minutes.
Frequently Asked Questions
How do you qualify mass tort leads?
Mass tort lead qualification starts with four hard disqualifiers: exposure or product use within the qualifying window, a physician-confirmed diagnosis tied to the specific tort injury, no prior settlement or trust claim for the same injury and product, and no existing representation by another attorney. Leads who clear those four gates move to a full intake that applies litigation-specific case criteria.
What makes a mass tort case viable?
A viable mass tort case typically requires confirmed product use or exposure within the litigation's qualifying time period, a formal medical diagnosis of the specific injury or condition the tort addresses, medical records that document that diagnosis, and a claimant who has not already resolved their claim through a prior settlement or bankruptcy trust. The specific criteria vary by litigation and are defined by the MDL case management orders or the settlement class definition.
How do intake teams screen mass tort claims?
Intake teams screen mass tort claims by running a short pre-screen that confirms the top hard disqualifiers before committing a case manager to a full intake call. The pre-screen typically covers exposure date, diagnosis status, prior claims, and representation status. Leads who pass the pre-screen move to a full intake that applies litigation-specific questions. Borderline leads route to a secondary review step rather than a binary decision.
What disqualifies a mass tort lead early?
The most common early disqualifiers are product use or exposure outside the qualifying date window, no formal diagnosis from a licensed provider tied to the specific tort injury, a prior settlement or bankruptcy trust claim already filed for the same injury and product, and existing representation by another attorney. Any one of these, confirmed at the pre-screen stage, ends the intake before case manager time is spent on the lead.
Why should disqualified mass tort leads be tagged with reason codes?
Reason codes capture why each lead failed the intake screen. When those codes are sent back to the ad platform as offline signals, tied to the click ID captured at first contact, the campaign algorithm can identify which audience segments, placements, and creative executions produce leads that consistently fail which disqualifier. Over time, the campaign bids away from those segments and toward the profiles that produce qualifying leads, lowering the cost per signed case.
Should mass tort intake use a pre-screen call or a full intake for every lead?
A pre-screen call of two to three minutes that confirms the top hard disqualifiers protects case manager capacity significantly more than running a full intake on every inbound lead. Case manager time is the constrained resource in mass tort intake. Filtering out clearly unqualifiable leads before they reach the full intake queue means case managers spend their time on leads that have already passed the hard criteria.
What is a secondary review step in mass tort intake?
A secondary review step is a named pipeline stage for leads with partial qualifying facts, a confirmed diagnosis but an uncertain exposure date, for example, that cannot be cleanly resolved by the pre-screen but should not be automatically disqualified. A designated reviewer examines the specific gap, determines whether it can be resolved, and either upgrades the lead to the full intake queue or disqualifies it with a reason code. This step recovers cases that a binary intake system would discard incorrectly.
How do litigation-specific intake questions differ from general intake questions?
General intake questions ask about injury and contact information. Litigation-specific questions ask about the particular facts the MDL or settlement class definition requires, such as a drug's NDC code and minimum duration of use for a pharmaceutical tort, or a device's model and lot number for a medical device tort. General questions pass leads who may still fail the litigation-specific screen. Firms need a separate question set for each active mass tort campaign, updated when the litigation's case criteria change.
How does mass tort lead qualification connect to ad campaign performance?
The connection runs through the CRM. Each lead carries a click ID from the original ad. When the lead is qualified or disqualified, the outcome and the disqualification reason code are sent back to the ad platform as offline conversion events tied to that click ID. The platform uses those signals to understand which audience attributes produce leads that sign and which produce leads that fail specific intake criteria. Over time, the campaign shifts budget toward the qualifying audience profiles, improving cost per signed case without changing the ad creative or the targeting settings manually.